PT3124610T - Tratamento do vhb - Google Patents

Tratamento do vhb

Info

Publication number
PT3124610T
PT3124610T PT16188642T PT16188642T PT3124610T PT 3124610 T PT3124610 T PT 3124610T PT 16188642 T PT16188642 T PT 16188642T PT 16188642 T PT16188642 T PT 16188642T PT 3124610 T PT3124610 T PT 3124610T
Authority
PT
Portugal
Prior art keywords
hbv treatment
hbv
treatment
Prior art date
Application number
PT16188642T
Other languages
English (en)
Inventor
Wayne Graham Michael
French Peter
Yuan Yuan Zhu York
Lu Yixiang
Li Tiejun
Sun Yuncheng
Tang Xiaojun
Shan Li
Original Assignee
Benitec Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201010522003.3A external-priority patent/CN101979557B/zh
Priority claimed from CN201010521972.7A external-priority patent/CN102021170B/zh
Priority claimed from CN201010521962.3A external-priority patent/CN101979554B/zh
Priority claimed from CN201010521975.0A external-priority patent/CN101979555B/zh
Priority claimed from CN201010521948.3A external-priority patent/CN101979553B/zh
Priority claimed from CN201010521990.5A external-priority patent/CN101979556B/zh
Priority claimed from CN201010522005.2A external-priority patent/CN101979558B/zh
Priority claimed from PCT/CN2011/071107 external-priority patent/WO2012109798A1/en
Application filed by Benitec Biopharma Ltd filed Critical Benitec Biopharma Ltd
Publication of PT3124610T publication Critical patent/PT3124610T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Control Of Eletrric Generators (AREA)
PT16188642T 2010-10-28 2011-10-27 Tratamento do vhb PT3124610T (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201010522003.3A CN101979557B (zh) 2010-10-28 2010-10-28 一种siRNA分子及其在抗病毒药物中的应用
CN201010521972.7A CN102021170B (zh) 2010-10-28 2010-10-28 一种干扰乙型肝炎病毒基因的siRNA分子及其应用
CN201010521962.3A CN101979554B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其应用
CN201010521975.0A CN101979555B (zh) 2010-10-28 2010-10-28 一种小干扰rna分子及其应用
CN201010521948.3A CN101979553B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其抗病毒应用
CN201010521990.5A CN101979556B (zh) 2010-10-28 2010-10-28 一种siRNA靶向分子及其应用
CN201010522005.2A CN101979558B (zh) 2010-10-28 2010-10-28 一种靶向乙型肝炎病毒基因的siRNA分子及其应用
PCT/CN2011/071107 WO2012109798A1 (en) 2011-02-18 2011-02-18 Hbv treatment

Publications (1)

Publication Number Publication Date
PT3124610T true PT3124610T (pt) 2019-06-14

Family

ID=45993174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16188642T PT3124610T (pt) 2010-10-28 2011-10-27 Tratamento do vhb

Country Status (20)

Country Link
US (2) US9080174B2 (pt)
EP (2) EP3124610B1 (pt)
KR (2) KR20180110186A (pt)
CN (1) CN103370415B (pt)
AU (1) AU2011320437B2 (pt)
BR (1) BR112013010525A2 (pt)
CA (1) CA2853613C (pt)
CY (1) CY1121894T1 (pt)
DK (1) DK3124610T3 (pt)
ES (1) ES2730393T3 (pt)
HR (1) HRP20190995T1 (pt)
HU (1) HUE044426T2 (pt)
LT (1) LT3124610T (pt)
PL (1) PL3124610T3 (pt)
PT (1) PT3124610T (pt)
RS (1) RS58982B1 (pt)
RU (1) RU2620966C2 (pt)
SI (1) SI3124610T1 (pt)
TR (1) TR201908127T4 (pt)
WO (1) WO2012055362A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201604074TA (en) 2011-04-21 2016-07-28 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN105002214B (zh) * 2015-04-08 2018-07-17 许中伟 用于载体表达的复合多联gRNA和RNAi的表达框架
JP7191690B2 (ja) * 2015-05-06 2022-12-19 ベニテック バイオファーマ リミテッド Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬及びその使用
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
AU2017235278C1 (en) 2016-03-14 2022-03-10 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of PD-L1 expression
CN109415733A (zh) 2016-05-05 2019-03-01 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
CN108929870B (zh) * 2017-05-19 2020-01-24 百奥迈科生物技术有限公司 抑制HBV的siRNA分子及其应用
WO2019076842A1 (en) 2017-10-16 2019-04-25 F. Hoffmann-La Roche Ag NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 MRNA FOR THE TREATMENT OF HEPATITIS B INFECTION
WO2019193165A1 (en) 2018-04-05 2019-10-10 F. Hoffmann-La Roche Ag Use of fubp1 inhibitors for treating hepatitis b virus infection
BR112020026973A2 (pt) 2018-07-03 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modulação da expressão tau
SG11202100348SA (en) 2018-07-13 2021-02-25 Hoffmann La Roche Oligonucleotides for modulating rtel1 expression
CN114829601A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
CN114901821A (zh) 2019-12-19 2022-08-12 豪夫迈·罗氏有限公司 Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
EP4077671A1 (en) 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of saraf inhibitors for treating hepatitis b virus infection
JP2023506547A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
WO2023111210A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combination of oligonucleotides for modulating rtel1 and fubp1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
SG115493A1 (en) 1998-03-20 2005-10-28 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US7919309B2 (en) 2001-09-13 2011-04-05 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
JP2006515162A (ja) 2002-08-29 2006-05-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 環状核酸ベクター、ならびに同ベクターの作製法および使用法
CA2527907A1 (en) 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded hairpin rnas for rnai
CN103060324B (zh) 2004-03-05 2015-04-01 贝尼泰克生物制药有限公司 用于RNAi试剂同时递送的多启动子表达盒
WO2006084209A2 (en) 2005-02-03 2006-08-10 Benitec, Inc. Rnai expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
US8129510B2 (en) 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
CN101684478B (zh) * 2009-06-26 2012-02-29 武汉大学 一种串联表达小干扰rna重组慢病毒载体的构建方法
CN101979556B (zh) * 2010-10-28 2015-01-21 百奥迈科生物技术有限公司 一种siRNA靶向分子及其应用

Also Published As

Publication number Publication date
KR20140071949A (ko) 2014-06-12
HUE044426T2 (hu) 2019-10-28
EP2633051A4 (en) 2014-04-23
WO2012055362A1 (en) 2012-05-03
US9410154B2 (en) 2016-08-09
EP3124610B1 (en) 2019-03-06
CA2853613C (en) 2020-03-24
RU2620966C2 (ru) 2017-05-30
BR112013010525A2 (pt) 2016-08-02
RS58982B1 (sr) 2019-08-30
AU2011320437A1 (en) 2013-06-13
ES2730393T3 (es) 2019-11-11
EP2633051A1 (en) 2013-09-04
CN103370415B (zh) 2017-05-31
PL3124610T3 (pl) 2019-09-30
TR201908127T4 (tr) 2019-06-21
HRP20190995T1 (hr) 2019-08-09
RU2013124422A (ru) 2014-12-10
CY1121894T1 (el) 2020-10-14
US20150344885A1 (en) 2015-12-03
KR20180110186A (ko) 2018-10-08
CA2853613A1 (en) 2012-05-03
US9080174B2 (en) 2015-07-14
CN103370415A (zh) 2013-10-23
DK3124610T3 (da) 2019-06-11
LT3124610T (lt) 2019-08-12
US20130296401A1 (en) 2013-11-07
SI3124610T1 (sl) 2019-08-30
AU2011320437B2 (en) 2017-03-16
EP3124610A1 (en) 2017-02-01
EP2633051B1 (en) 2016-09-14
KR101903778B1 (ko) 2018-10-04

Similar Documents

Publication Publication Date Title
EP2633051A4 (en) TREATMENT OF HBV INFECTION
PL2652193T3 (pl) Obróbka
EP2611496A4 (en) Methods of Treatment
GB2478797B (en) Waste treatment
ZA201205425B (en) Treatment with vb-201
GB0900599D0 (en) Treatment
GB201013573D0 (en) Treatment
EP2560679A4 (en) TREATMENT OF ECZEMA
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
ZA201308117B (en) Avian-based treatment
GB201014097D0 (en) Treatment
GB201021319D0 (en) Treatment
GB2483219B (en) Surface Treatment
GB201014736D0 (en) Treatment of hepatitis C
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102263D0 (en) Treatment